Search Results

Biotech Beach

OncoSec is encouraged after FDA meeting to discuss proposed neoadjuvant melanoma clinical program

OncoSec Medical Incorporated (NASDAQ: ONCS) (the Company or OncoSec) today announced a Type C meeting held with the US Food and Drug Administration (FDA) on May 15, 2023.

May 16, 2023

·

8 min read

Biotech Beach

OncoSec Announces Closing of $1.33 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules

OncoSec Medical Incorporated announced the closing of its previously announced registered direct offering of 1,408,384 shares of its common stock, at a purchase price of $0.945 per share, priced at-the-market under Nasdaq rules.

May 18, 2023

·

7 min read

Biotech Beach

OncoSec Receives $3.49 Million to Strengthen its Balance Sheet After Selling its Net Operating Loss Tax Benefits Through The New Jersey Economic Development Authority NOL Program

OncoSec Medical Incorporated today announced the receipt of $3.49 million in tax credit certificates from the New Jersey Economic Development Authority (NJEDA).

April 27, 2023

·

5 min read

Biotech Beach

OncoSec Announces Reverse Stock Split - November 08, 2022

OncoSec Medical Incorporated announced it intends to effect a 1-for-22 reverse split of its issued and outstanding common stock.

November 8, 2022

·

4 min read

Biotech Beach

OncoSec Announces Closing of $2 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules

OncoSec Medical Incorporated announced the closing of its previously announced registered direct offering of 1,582,932 shares of its common stock, at a purchase price of $1.25 per share, priced at-the-market under Nasdaq rules.

April 11, 2023

·

6 min read

Drug Development

OncoSec Announces Clinical Data of the KEYNOTE-695 Trial Assessing TAVO™-EP in Combination with KEYTRUDA® (pembrolizumab) in Patients with Advanced Melanoma Refractory to anti-PD-1 Treatment

OncoSec Medical Incorporated (NASDAQ: ONCS) (the Company or OncoSec), a clinical-stage biotechnology company developing intratumoral immunotherapies to stimulate the patient’s immune system to target cancer cells and eradicate disease, today announced primary endpoint data from the Phase 2 KEYNOTE-695 clinical trial.

April 3, 2023

·

8 min read

Biotech Beach

OncoSec Announces $2 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules

OncoSec Medical Incorporated announced that it has entered into a definitive agreement for the purchase and sale of an aggregate of 1,582,932 shares of its common stock, at a purchase price of $1.25 per share, in a registered direct offering priced at-the-market under Nasdaq rules.

April 10, 2023

·

7 min read

Biotech Beach

OncoSec presents encouraging early data with TAVO™-EP combined with nivolumab (Opdivo®) in neoadjuvant melanoma

OncoSec Medical Incorporated (NASDAQ: ONCS) (the “Company” or “OncoSec”) today announced early clinical data from an investigator-sponsored trial (IST) conducted by Dr. Ahmad Tarhini at the H. Lee Moffit Cancer Center & Research Institute.

November 15, 2022

·

7 min read

Business

OncoSec Announces Pipeline Prioritization and Workforce Reduction

OncoSec Medical Incorporated announced a corporate restructuring intended to prioritize development of its lead clinical candidate TAVO™ a plasmid encoding interleukin 12 delivered by intratumoral electroporation, and extend the Company’s cash runway.

October 4, 2022

·

5 min read

Drug Development

OncoSec Announces Positive Clinical Data of the KEYNOTE-695 Trial Assessing TAVO-EP in Combination with Pembrolizumab (Keytruda®) in Patients with Advanced Melanoma Refractory to anti-PD-1 Treatment

OncoSec Medical Incorporated today announced data from the Phase 2 KEYNOTE-695 clinical trial.

November 11, 2022

·

6 min read